<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096534</url>
  </required_header>
  <id_info>
    <org_study_id>NORPN</org_study_id>
    <nct_id>NCT04096534</nct_id>
  </id_info>
  <brief_title>Normotonic Partial Nephrectomy as Novel Approach in Treating Small Renal Masses</brief_title>
  <acronym>NORPN</acronym>
  <official_title>Normotonic Partial Nephrectomy as Novel Approach in Treating Small Renal Masses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Petersburg State University, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Petersburg State University, Russia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates novel surgical approach in treating small renal masses. Half of
      participants will undergo hypotonic zero-ischaemia partial nephrectomy (standard of care),
      while the other half will undergo normotonic zero-ischaemia partial nephrectomy (experimental
      method).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Partial nephrectomy is believed to be the gold standard for treating small renal masses
      (SRM). The warm ischaemia and hypotonic zero-ischaemia approach are widely used techniques of
      care. But they have some negative effects according to renal function (RF) after surgery. We
      decided to compare influence of arterial blood pressure (normotension or hypotension) during
      partial nephrectomy on RF.

      A single-center prospective study comparing normotonic and hypotonic partial nephrectomy will
      be conducted.

      The design involves random allocation of eligible patients to normotonic or hypotonic partial
      nephrectomy group in 1:1 ratio.

      Experimental group - normotonic partial nephrectomy (avoidance of hypotension: mean blood
      pressure more or equal 65 mm Hg).

      Control group - hypotonic partial nephrectomy (using medical hypotension; avoidance of
      hypertension: mean blood pressure less than 65 mmHg

      According to preliminary calculations, taking into account type I error of 5% and power of
      80%, 100 patients should be included in the study. In order to compensate for data loss, the
      estimated sample size is increased by 10%. As a result, the total sample size is 100 +10 =
      110 patients (55 patients for each group). The expected duration of the study is 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">October 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function</measure>
    <time_frame>within the first 3 month after surgery</time_frame>
    <description>glomerular filtration rate calculation (mL/min), nephroscintigraphy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>enrollment</time_frame>
    <description>Volume of intraoperative blood loss (ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year after last patient enrolled</time_frame>
    <description>Survival without local or systemic recurrence (months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection margins status</measure>
    <time_frame>enrollment</time_frame>
    <description>Evaluating of resection margins status (positive/negative)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Renal Malignant Tumor</condition>
  <condition>Renal Tumor</condition>
  <arm_group>
    <arm_group_label>Normotonic partial nephrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Performing a partial nephrectomy under normal body blood pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypotonic partial nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performing a partial nephrectomy under hypotonic body blood pressure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normotonic partial nephrectomy</intervention_name>
    <description>partial nephrectomy performing with avoidance of hypotension: mean blood pressure more or equal 65 mm Hg</description>
    <arm_group_label>Normotonic partial nephrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypotonic partial nephrectomy</intervention_name>
    <description>partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: mean blood pressure less than 65 mmHg</description>
    <arm_group_label>Hypotonic partial nephrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected by computed tomography or another instrumental method renal mass

          -  Clinical stage T1-2N0-2M0-1 (distant metastases must be resectable)

          -  Indications for partial nephrectomy

          -  Eastern Cooperative Oncology Group status 0-2

          -  At least 18 years of age

          -  Written informed consent

        Exclusion Criteria:

          -  Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent or comply with the study protocol

          -  Pregnancy or breast feeding

          -  Medical contraindications for surgical treatment

          -  Synchronous or metachronous malignancy

          -  Non-resectable distant metastases

          -  The patient's refusal to perform research procedures.

          -  Refusal of the patient to continue participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imran Dzhalilov, MD</last_name>
    <role>Study Director</role>
    <affiliation>Saint Petersburg State University, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladislav Osetnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Petersburg State University, Russia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Batyrbek Aslanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mechnikov North-West State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladislav Osetnik, MD</last_name>
    <phone>89312064346</phone>
    <email>osetnik@bk.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eldar Mamijev, MD</last_name>
    <phone>89217696923</phone>
    <email>mamijev@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>State University Clinic</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladislav Osetnik, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Petersburg State University, Russia</investigator_affiliation>
    <investigator_full_name>Vladislav Osetnik</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>partial nephrectomy</keyword>
  <keyword>zero ischaemia</keyword>
  <keyword>renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are not planning to share personal patient data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

